(CME) CME - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US12572Q1058
Futures, Options, Swaps, Clearing, Data
Dividends
| Dividend Yield | 3.95% |
| Yield on Cost 5y | 7.46% |
| Yield CAGR 5y | 15.22% |
| Payout Consistency | 93.1% |
| Payout Ratio | 45.6% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 17.3% |
| Value at Risk 5%th | 29.0% |
| Relative Tail Risk | 2.01% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.95 |
| Alpha | 16.06 |
| CAGR/Max DD | 1.95 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.423 |
| Beta | -0.079 |
| Beta Downside | -0.029 |
| Drawdowns 3y | |
|---|---|
| Max DD | 11.65% |
| Mean DD | 3.57% |
| Median DD | 2.99% |
Description: CME CME December 02, 2025
CME Group Inc. (NASDAQ:CME) operates the world’s largest derivatives exchange platform, offering futures and options across interest rates, equity indexes, FX, agricultural commodities, energy, and metals, plus clearing, settlement, and risk-mitigation services for both exchange-traded and cleared-swap products.
Key operational metrics illustrate its market dominance: in 2023 the firm generated ≈ $5.5 billion in net revenue, processed over 30 billion contracts through its clearinghouse, and holds roughly 50 % market share in U.S. interest-rate futures-a segment that reacts sharply to Federal Reserve policy cycles.
Sector-level drivers that materially affect CME’s topline include (1) central-bank rate moves, which boost trading volume in Treasury-linked futures; (2) commodity price volatility, especially in energy and agricultural markets, which fuels demand for hedging instruments; and (3) the ongoing migration of institutional trading to electronic platforms, enhancing CME’s data-service revenue streams.
For a deeper, data-driven view of CME’s valuation dynamics, a quick look at ValueRay’s analyst toolkit can surface the quantitative levers most likely to move the stock price.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (3.75b TTM) > 0 and > 6% of Revenue (6% = 383.8m TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA -0.45pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 50.23% (prev 38.40%; Δ 11.83pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.02 (>3.0%) and CFO 4.16b > Net Income 3.75b (YES >=105%, WARN >=100%) |
| Net Debt (968.0m) to EBITDA (5.35b) ratio: 0.18 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (360.3m) change vs 12m ago 0.09% (target <= -2.0% for YES) |
| Gross Margin 86.14% (prev 86.06%; Δ 0.08pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 3.94% (prev 4.39%; Δ -0.45pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 29.45 (EBITDA TTM 5.35b / Interest Expense TTM 170.4m) >= 6 (WARN >= 3) |
Altman Z'' 0.46
| (A) 0.02 = (Total Current Assets 152.80b - Total Current Liabilities 149.59b) / Total Assets 187.14b |
| (B) 0.03 = Retained Earnings (Balance) 5.71b / Total Assets 187.14b |
| (C) 0.03 = EBIT TTM 5.02b / Avg Total Assets 162.47b |
| (D) 0.04 = Book Value of Equity 5.75b / Total Liabilities 158.95b |
| Total Rating: 0.46 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 84.08
| 1. Piotroski 3.50pt |
| 2. FCF Yield 3.99% |
| 3. FCF Margin 63.84% |
| 4. Debt/Equity 0.12 |
| 5. Debt/Ebitda 0.18 |
| 6. ROIC - WACC (= 7.01)% |
| 7. RoE 13.71% |
| 8. Rev. Trend 89.99% |
| 9. EPS Trend 89.11% |
What is the price of CME shares?
As of December 14, 2025, the stock is trading at USD 273.55 with a total of 1,444,179 shares traded.
Over the past week, the price has changed by +1.45%, over one month by -1.71%, over three months by +4.77% and over the past year by +21.08%.
Over the past week, the price has changed by +1.45%, over one month by -1.71%, over three months by +4.77% and over the past year by +21.08%.
Is CME a buy, sell or hold?
CME has received a consensus analysts rating of 3.39.
Therefor, it is recommend to hold CME.
- Strong Buy: 4
- Buy: 3
- Hold: 7
- Sell: 4
- Strong Sell: 0
What are the forecasts/targets for the CME price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 284.1 | 3.8% |
| Analysts Target Price | 284.1 | 3.8% |
| ValueRay Target Price | 330.6 | 20.8% |
CME Fundamental Data Overview December 02, 2025
Market Cap USD = 101.49b (101.49b USD * 1.0 USD.USD)
P/E Trailing = 27.2469
P/E Forward = 24.2718
P/S = 15.8953
P/B = 3.6003
P/EG = 5.9521
Beta = 0.297
Revenue TTM = 6.40b USD
EBIT TTM = 5.02b USD
EBITDA TTM = 5.35b USD
Long Term Debt = 3.42b USD (from longTermDebt, last quarter)
Short Term Debt = 749.8m USD (from shortTermDebt, last fiscal year)
Debt = 3.42b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 968.0m USD (from netDebt column, last quarter)
Enterprise Value = 102.34b USD (101.49b + Debt 3.42b - CCE 2.58b)
Interest Coverage Ratio = 29.45 (Ebit TTM 5.02b / Interest Expense TTM 170.4m)
FCF Yield = 3.99% (FCF TTM 4.08b / Enterprise Value 102.34b)
FCF Margin = 63.84% (FCF TTM 4.08b / Revenue TTM 6.40b)
Net Margin = 58.64% (Net Income TTM 3.75b / Revenue TTM 6.40b)
Gross Margin = 86.14% ((Revenue TTM 6.40b - Cost of Revenue TTM 886.7m) / Revenue TTM)
Gross Margin QoQ = 84.55% (prev 86.90%)
Tobins Q-Ratio = 0.55 (Enterprise Value 102.34b / Total Assets 187.14b)
Interest Expense / Debt = 1.29% (Interest Expense 44.0m / Debt 3.42b)
Taxrate = 22.85% (269.0m / 1.18b)
NOPAT = 3.87b (EBIT 5.02b * (1 - 22.85%))
Current Ratio = 1.02 (Total Current Assets 152.80b / Total Current Liabilities 149.59b)
Debt / Equity = 0.12 (Debt 3.42b / totalStockholderEquity, last quarter 28.19b)
Debt / EBITDA = 0.18 (Net Debt 968.0m / EBITDA 5.35b)
Debt / FCF = 0.24 (Net Debt 968.0m / FCF TTM 4.08b)
Total Stockholder Equity = 27.36b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.00% (Net Income 3.75b / Total Assets 187.14b)
RoE = 13.71% (Net Income TTM 3.75b / Total Stockholder Equity 27.36b)
RoCE = 16.30% (EBIT 5.02b / Capital Employed (Equity 27.36b + L.T.Debt 3.42b))
RoIC = 12.58% (NOPAT 3.87b / Invested Capital 30.78b)
WACC = 5.57% (E(101.49b)/V(104.92b) * Re(5.72%) + D(3.42b)/V(104.92b) * Rd(1.29%) * (1-Tc(0.23)))
Discount Rate = 5.72% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.09%
[DCF Debug] Terminal Value 79.84% ; FCFE base≈3.90b ; Y1≈4.37b ; Y5≈5.81b
Fair Price DCF = 279.2 (DCF Value 100.69b / Shares Outstanding 360.6m; 5y FCF grow 13.81% → 3.0% )
EPS Correlation: 89.11 | EPS CAGR: 13.62% | SUE: -0.91 | # QB: 0
Revenue Correlation: 89.99 | Revenue CAGR: 8.12% | SUE: 0.54 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.90 | Chg30d=+0.006 | Revisions Net=+0 | Analysts=10
EPS next Year (2026-12-31): EPS=11.63 | Chg30d=+0.030 | Revisions Net=+3 | Growth EPS=+4.5% | Growth Revenue=+4.6%
P/E Trailing = 27.2469
P/E Forward = 24.2718
P/S = 15.8953
P/B = 3.6003
P/EG = 5.9521
Beta = 0.297
Revenue TTM = 6.40b USD
EBIT TTM = 5.02b USD
EBITDA TTM = 5.35b USD
Long Term Debt = 3.42b USD (from longTermDebt, last quarter)
Short Term Debt = 749.8m USD (from shortTermDebt, last fiscal year)
Debt = 3.42b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 968.0m USD (from netDebt column, last quarter)
Enterprise Value = 102.34b USD (101.49b + Debt 3.42b - CCE 2.58b)
Interest Coverage Ratio = 29.45 (Ebit TTM 5.02b / Interest Expense TTM 170.4m)
FCF Yield = 3.99% (FCF TTM 4.08b / Enterprise Value 102.34b)
FCF Margin = 63.84% (FCF TTM 4.08b / Revenue TTM 6.40b)
Net Margin = 58.64% (Net Income TTM 3.75b / Revenue TTM 6.40b)
Gross Margin = 86.14% ((Revenue TTM 6.40b - Cost of Revenue TTM 886.7m) / Revenue TTM)
Gross Margin QoQ = 84.55% (prev 86.90%)
Tobins Q-Ratio = 0.55 (Enterprise Value 102.34b / Total Assets 187.14b)
Interest Expense / Debt = 1.29% (Interest Expense 44.0m / Debt 3.42b)
Taxrate = 22.85% (269.0m / 1.18b)
NOPAT = 3.87b (EBIT 5.02b * (1 - 22.85%))
Current Ratio = 1.02 (Total Current Assets 152.80b / Total Current Liabilities 149.59b)
Debt / Equity = 0.12 (Debt 3.42b / totalStockholderEquity, last quarter 28.19b)
Debt / EBITDA = 0.18 (Net Debt 968.0m / EBITDA 5.35b)
Debt / FCF = 0.24 (Net Debt 968.0m / FCF TTM 4.08b)
Total Stockholder Equity = 27.36b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.00% (Net Income 3.75b / Total Assets 187.14b)
RoE = 13.71% (Net Income TTM 3.75b / Total Stockholder Equity 27.36b)
RoCE = 16.30% (EBIT 5.02b / Capital Employed (Equity 27.36b + L.T.Debt 3.42b))
RoIC = 12.58% (NOPAT 3.87b / Invested Capital 30.78b)
WACC = 5.57% (E(101.49b)/V(104.92b) * Re(5.72%) + D(3.42b)/V(104.92b) * Rd(1.29%) * (1-Tc(0.23)))
Discount Rate = 5.72% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.09%
[DCF Debug] Terminal Value 79.84% ; FCFE base≈3.90b ; Y1≈4.37b ; Y5≈5.81b
Fair Price DCF = 279.2 (DCF Value 100.69b / Shares Outstanding 360.6m; 5y FCF grow 13.81% → 3.0% )
EPS Correlation: 89.11 | EPS CAGR: 13.62% | SUE: -0.91 | # QB: 0
Revenue Correlation: 89.99 | Revenue CAGR: 8.12% | SUE: 0.54 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.90 | Chg30d=+0.006 | Revisions Net=+0 | Analysts=10
EPS next Year (2026-12-31): EPS=11.63 | Chg30d=+0.030 | Revisions Net=+3 | Growth EPS=+4.5% | Growth Revenue=+4.6%
Additional Sources for CME Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle